Top

Published in:

01-02-2019 | Clinical Management of Endocrine Diseases

Skeletal fragility: an emerging complication of Ehlers–Danlos syndrome

Authors: Anna Maria Formenti, Mauro Doga, Stefano Frara, Marco Ritelli, Marina Colombi, Giuseppe Banfi, Andrea Giustina

Published in: Endocrine | Issue 2/2019

Abstract

Ehlers–Danlos syndrome (EDS) is an emerging cause of skeletal fragility. Mechanism of bone damage are probably multifactorial in line with the different skeletal phenotypes that can be found in clinical practice. A structured approach to clinical management of bone metabolic complication in EDS is proposed.

B. Steinmann, P.M. Royce, A. Superti-Furga, in: Connective Tissue and Its Heritable Disorders, ed. by P.M. Royce, B. Steinmann (Wiley-Liss: New York, NY, USA, 2002), pp. 431–524

F. Malfait, C. Francomano, P. Byers, J. Belmont, B. Berglund et al. The 2017 international classification of the Ehlers–Danlos syndromes. Am. J. Med. Genet. 175C, 8–26 (2017)CrossRef

M. Colombi, C. Dordoni, N. Chiarelli, M. Ritelli, Differential diagnosis and diagnostic flow chart of joint hypermobility syndrome/Ehlers–Danlos syndrome hypermobility type compared to other heritable connective tissue disorders. Am. J. Med. Genet. 169, 6–22 (2015)CrossRef

M. Ritelli, M. Venturini, C. Dordoni, N. Chiarelli, S. Quinzani et al. Clinical and molecular characterization of 40 patients with classic Ehlers-Danlos syndrome: identification of 18 COL5A1 and 2 COL5A2 novel mutations. Orphanet. J. Rare. Dis. 8, 58 (2013)CrossRefPubMedPubMedCentral

M. Colombi, C. Dordoni, M. Venturini, C. Ciaccio, S. Morlino et al. Spectrum of mucocutaneous, ocular and facial features and delineation of novel presentations in 62 classical Ehlers-Danlos syndrome patients. Clin. Genet. 92, 624–631 (2017)CrossRefPubMed

M. Castori, B. Tinkle, H. Levy, R. Grahame, F. Malfait, A. Hakim, A framework for the classification of joint hypermobility and related conditions. A continuous spectrum of phenotypes exists grouping together patients with isolated, non-syndromic joint hypermobility, HSD and hEDS. Am. J. Med. Genet. C. Semin. Med. Genet. 175(1), 148–157 (2017)CrossRefPubMed

M. Castori, A. Hakim, Contemporary approach to joint hypermobility and related disorders. Curr. Opin. Pediatr. 29(6), 640–649 (2017)CrossRefPubMed

Y. Gazit, G. Jacob, R. Grahame, Ehlers–Danlos syndrome—hypermobility type: a much neglected multisystemic disorder. Rambam Maimonides Med 7, 1–10 (2016)

A.A. Deodhar, A.D. Woolf, Ehlers-Danlos syndrome and osteoporosis. Ann. Rheum. Dis. 53, 841–842 (1994)CrossRefPubMedPubMedCentral

10.

P.C. Coelho, R. Santos, J.A. Gomes, Osteoporosis and Ehlers-Danlos syndrome. Ann. Rheum. Dis. 53, 212–213 (1994)CrossRefPubMedPubMedCentral

11.

A.L. Dolan, N.K. Arden, R. Grahame, T.D. Spector, Assessment of bone in Ehlers Danlos syndrome by ultrasound and densitometry. Ann. Rheum. Dis. 57, 630–633 (1998)CrossRefPubMedPubMedCentral

12.

G. Mazziotti, C. Dordoni, M. Doga, F. Galderisi et al. High prevalence of radiological vertebral fractures in adult patients with Ehlers–Danlos syndrome. Bone 84, 88–92 (2016)CrossRefPubMed

13.

C. Eller-Vainicher, A. Bassotti, A. Imeraj, E. Cairoli et al. Bone involvement in adult patients affected with Ehlers-Danlos syndrome. Osteoporos. Int. 27, 2525–2531 (2016)CrossRefPubMed

14.

S. Bonadonna, G. Mazziotti, M. Nuzzo, A. Bianchi et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J. Bone Miner. Res. 30, 1837–1844 (2005)CrossRef

15.

G. Mazziotti, M. Doga, S. Frara, F. Maffezzoni et al. Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. Endocrine 52, 103–110 (2016)CrossRefPubMed

16.

G. Mazziotti, A. Delgado, F. Maffezzoni, A. Formenti et al. Skeletal fragility in endogenous hypercortisolism. Front. Horm. Res. 46, 66–73 (2016)CrossRefPubMed

17.

P. Beighton, A. De Paepe, B. Steinmann, P. Tsipouras et al. Ehlers–Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers–Danlos National Foundation (USA) and Ehlers–Danlos Support Group (UK). Am. J. Med. Genet. 77, 31–37 (1998)CrossRefPubMed

18.

J.T. Schousboe, J.A. Shepherd, J.P. Bilezikian et al. Executive summary of the2013 International Society for Clinical Densitometry position development conference on bone densitometry. J. Clin. Densitom. 16, 455–466 (2013)CrossRefPubMed

19.

J.F. Griffith, H.K. Genant, New advances in imaging osteoporosis and its complications. Endocrine 42, 39–51 (2012)CrossRefPubMed

20.

R.T. Franceschi, The developmental control of osteoblast specific gene expression: role of specific transcription factors and the extracellular matrix environment. Crit. Rev. Oral. Biol. Med. 10, 40–57 (1999)CrossRefPubMed

21.

C. Ge, Q. Yang, G. Zhao, H. Yu et al. Interactions between extracellular signal-regulated kinase 1/2 and p38 MAP kinase pathways in the control of RUNX2 phosphorylation and transcriptional activity. J. Bone Miner. Res. 27, 538–551 (2012)CrossRefPubMedPubMedCentral

22.

G.S. Schultz, J.M. Davidson, R.S. Kirsner, P. Bornstein et al. Dynamic reciprocity in the wound microenvironment. Wound Rep. Reg. 19, 134–148 (2011)CrossRef

23.

T. Palomo, T. Vilaça, M. Lazaretti-Castro, Osteogenesis imperfecta: diagnosis and treatment. Curr. Opin. Endocrinol. Diabetes Obes. 24, 381–388 (2017)CrossRefPubMed

24.

M. Fiscaletti, C.P. Coorey, A. Biggin, J. Briody, Diagnosis of recurrent fractures in a pediatric cohort. Calcif. Tissue Int. 103(5), 529–539 (2018). https://doi.org/10.1007/s00223-018-0449-6 CrossRefPubMed

25.

J. Lim, I. Grafe, S. Alexander, B. Lee, Genetic causes and mechanisms of osteogenesis imperfecta. Bone 102, 40–49 (2017)CrossRefPubMedPubMedCentral

26.

N. Chiarelli, G. Carini, N. Zoppi, C. Dordoni, M. Ritelli, M. Venturini, M. Castori, M. Colombi, Transcriptome-wide expression profiling in skin fibroblasts of patients with joint hypermobility syndrome/Ehlers–Danlos syndrome hypermobility type. PLoS ONE 11(8), e0161347 (2016)CrossRefPubMedPubMedCentral

27.

N. Zoppi, N. Chiarelli, S. Binetti, M. Ritelli, M. Colombi, Dermal fibroblast-to-myofibroblast transition sustained by αvß3 integrin-ILK-Snail1/Slug signaling is a common feature for hypermobile Ehlers–Danlos syndrome and hypermobility spectrum disorders. Biochem Biophys. Acta 1864(4 Pt A), 1010–1023 (2018)

28.

S. Shuster, Osteoporosis, a unitary hypothesis of collagen loss in skin and bone. Med. Hypotheses 65, 426–432 (2005)CrossRefPubMed

29.

L. Carbone, F.A. Tylavsky, A.J. Bush, W. Koo et al. Bone density in Ehlers–Danlos syndrome. Osteoporos. Int. 11, 388–392 (2000)CrossRefPubMed

30.

M.F. Holick, A. Hossein-Nezhad, F. Tabatabaei, Multiple fractures in infants who have Ehlers–Danlos/hypermobility syndrome and or vitamin D deficiency: a case series of 72 infants whose parents were accused of child abuse and neglect. Dermatoendocrinol 9(1), e1279768 (2017). https://doi.org/10.1080/19381980.2017.1279768 CrossRefPubMedPubMedCentral

31.

M. Yamashita, K. Hasegawa, Y. Higuchi, T. Miyai et al. Urinary cross-linked N-terminal telopeptide of type I collagen levels of infants with Osteogenesis Imperfecta and healthy infants. Acta Med. Okayama 70, 435–439 (2016)PubMed

32.

E. Aström, P. Magusson, S. Eksborg, S. Söderhäll, Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with Osteogenesis Imperfecta. Acta Paediatr. 99, 1834–1840 (2010)CrossRefPubMed

33.

G. Mazziotti, A.M. Formenti, S. Frara, R. Olivetti et al. High prevalence of radiological vertebral fractures in women on thyroid-stimulating hormone-suppressive therapy for thyroid carcinoma. J. Clin. Endocrinol. Metab. 103, 956–964 (2017)CrossRef

34.

D. Diacinti, D. Pisani, M. D”Avanzo, M. Celli et al. Reliability of vertebral fractures assessment (VFA) in children with Osteogenesis Imperfecta. Calcif. Tissue 96, 307–312 (2015)CrossRef

35.

C. Grey, R. Young, P.W. Bearcroft, J.E. Compston, Vertebral deformity in the thoracic spine in post-menopausal women: value of lumbar spine bone density. Br. J. Radiol. 69, 137–42 (1996)CrossRefPubMed

36.

G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41, 58–69 (2012)CrossRefPubMed

37.

G. Mazziotti, S. Frara, A. Giustina, Pituitary diseases and bone. Endocr. Rev. 39, 440–488 (2018). https://doi.org/10.1210/err.2018-00005 CrossRefPubMed

Title: Skeletal fragility: an emerging complication of Ehlers–Danlos syndrome
Authors: Anna Maria Formenti
Mauro Doga
Stefano Frara
Marco Ritelli
Marina Colombi
Giuseppe Banfi
Andrea Giustina
Publication date: 01-02-2019
Publisher: Springer US
Published in: Endocrine / Issue 2/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-018-1822-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Skeletal fragility: an emerging complication of Ehlers–Danlos syndrome

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Association between age at menopause and fracture risk: a systematic review and meta-analysis

Molecular genetics and phenotype/genotype correlation of 5-α reductase deficiency in a highly consanguineous population

Is calcitonin gene-related peptide a modulator of menopausal vasomotor symptoms?

Correction to: Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: influence of the disease severity and therapy on the ovarian reserve

Assessing the predictive accuracy of oral glucose effectiveness index using a calibration model

Long-term remission following antithyroid drug withdrawal in patients with Graves’ hyperthyroidism: parameters with prognostic value

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page